Deutsche Bank’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.31M | Buy |
120,368
+15,282
| +15% | +$304K | ﹤0.01% | 1698 |
|
|
2025
Q4 | $1.73M | Sell |
105,086
-102,508
| -49% | -$1.73M | ﹤0.01% | 1873 |
|
|
2025
Q3 | $3.01M | Buy |
207,594
+71,625
| +53% | +$1.03M | ﹤0.01% | 1539 |
|
|
2025
Q2 | $1.9M | Sell |
135,969
-20,283
| -13% | -$285K | ﹤0.01% | 1737 |
|
|
2025
Q1 | $2.13M | Sell |
156,252
-121,601
| -44% | -$2.33M | ﹤0.01% | 1705 |
|
|
2024
Q4 | $5.66M | Buy |
277,853
+37,907
| +16% | +$970K | ﹤0.01% | 1278 |
|
|
2024
Q3 | $6.99M | Buy |
239,946
+16,546
| +7% | +$410K | ﹤0.01% | 1143 |
|
|
2024
Q2 | $5.19M | Sell |
223,400
-7,031
| -3% | -$135K | ﹤0.01% | 1234 |
|
|
2024
Q1 | $4.73M | Buy |
230,431
+115,079
| +100% | +$2.16M | ﹤0.01% | 1289 |
|
|
2023
Q4 | $2.48M | Sell |
115,352
-1,146
| -1% | -$22.7K | ﹤0.01% | 1566 |
|
|
2023
Q3 | $2.4M | Sell |
116,498
-28,379
| -20% | -$720K | ﹤0.01% | 1286 |
|
|
2023
Q2 | $4.28M | Buy |
144,877
+14,148
| +11% | +$398K | ﹤0.01% | 1298 |
|
|
2023
Q1 | $3.01M | Buy |
130,729
+19,999
| +18% | +$550K | ﹤0.01% | 1461 |
|
|
2022
Q4 | $3.08M | Buy |
110,730
+9,880
| +10% | +$294K | ﹤0.01% | 1426 |
|
|
2022
Q3 | $3.1M | Sell |
100,850
-9,447
| -9% | -$307K | ﹤0.01% | 1411 |
|
|
2022
Q2 | $3.25M | Sell |
110,297
-2,617
| -2% | -$68.6K | ﹤0.01% | 1495 |
|
|
2022
Q1 | $3.63M | Sell |
112,914
-5,418
| -5% | -$186K | ﹤0.01% | 1549 |
|
|
2021
Q4 | $5.28M | Buy |
118,332
+2,316
| +2% | +$110K | ﹤0.01% | 1409 |
|
|
2021
Q3 | $5.85M | Sell |
116,016
-1,022
| -0.9% | -$57.6K | ﹤0.01% | 1414 |
|
|
2021
Q2 | $9.18M | Buy |
117,038
+58,249
| +99% | +$3.6M | ﹤0.01% | 1215 |
|
|
2021
Q1 | $3.36M | Buy |
58,789
+6,902
| +13% | +$462K | ﹤0.01% | 1818 |
|
|
2020
Q4 | $4.35M | Buy |
51,887
+11,110
| +27% | +$672K | ﹤0.01% | 1433 |
|
|
2020
Q3 | $1.46M | Sell |
40,777
-845
| -2% | -$25.4K | ﹤0.01% | 1936 |
|
|
2020
Q2 | $1.01M | Sell |
41,622
-29,177
| -41% | -$686K | ﹤0.01% | 2217 |
|
|
2020
Q1 | $1.24M | Sell |
70,799
-13,407
| -16% | -$280K | ﹤0.01% | 1970 |
|
|
2019
Q4 | $1.47M | Sell |
84,206
-19,784
| -19% | -$329K | ﹤0.01% | 2157 |
|
|
2019
Q3 | $1.59M | Buy |
103,990
+55,122
| +113% | +$1.05M | ﹤0.01% | 2041 |
|
|
2019
Q2 | $1.01M | Buy |
48,868
+22,549
| +86% | +$505K | ﹤0.01% | 2833 |
|
|
2019
Q1 | $608K | Sell |
26,319
-849
| -3% | -$17.8K | ﹤0.01% | 3326 |
|
|
2018
Q4 | $561K | Sell |
27,168
-76,228
| -74% | -$1.38M | ﹤0.01% | 3250 |
|
|
2018
Q3 | $2.25M | Buy |
103,396
+69,628
| +206% | +$1.15M | ﹤0.01% | 2780 |
|
|
2018
Q2 | $514K | Buy |
33,768
+12,536
| +59% | +$236K | ﹤0.01% | 3829 |
|
|
2018
Q1 | $417K | Buy |
+21,232
| New | +$437K | ﹤0.01% | 3807 |
|
Other funds holding DNLI
VCM
VPM
Deutsche Bank's DNLI Position: Q1 2026 in Review
Deutsche Bank increased its Denali Therapeutics (DNLI) stake by 15% in Q1 2026, buying an estimated $304K and bringing the position to 120,368 shares worth $2.31M. The position accounts for ﹤0.01% of the portfolio, ranked #1698.
Deutsche Bank first reported a position in DNLI in Q1 2018 and has held it in 33 quarters since. The position peaked at $9.18M in Q2 2021. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.
- Deutsche Bank held 120,368 shares of Denali Therapeutics worth $2.31M as of Q1 2026.
- Deutsche Bank bought 15,282 Denali Therapeutics shares in Q1 2026, an estimated $304K.
- Denali Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #1698 holding.
- Deutsche Bank first reported a position in Denali Therapeutics in Q1 2018 and has held it in 33 quarters since.
- Deutsche Bank's Denali Therapeutics position peaked at $9.18M in Q2 2021.
- 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.
Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.